Global burden and trends in premenopausal and postmenopausal breast cancer: a population-based study

Abstract

Background Breast cancer has distinct causes, prognoses, and outcomes and effects in patients at premenopausal and postmenopausal ages. We sought to assess the global burden and trends in breast cancer by menopausal status. MethodsWe did a population-based analysis of global breast cancer incidence and mortality among premenopausal and postmenopausal women. Menopausal status was defined using age as a proxy, whereby breast cancer cases or deaths at age 50 years or older were regarded as postmenopausal. Age-standardised breast cancer incidence and mortality in 2018 were calculated using GLOBOCAN data. Incidence trends for 1998-2012 were assessed in 44 populations from 41 countries using the Cancer in Five Continents plus database, by calculating the annual average percent change.Findings Approximately 645 000 premenopausal and 1•4 million postmenopausal breast cancer cases were diagnosed worldwide in 2018, with more than 130 000 and 490 000 deaths occurring in each menopausal group, respectively. Proportionally, countries with a low UNDP human development index (HDI) faced a greater burden of premenopausal breast cancer for both new cases and deaths compared with higher income countries. Countries with a very high HDI had the highest premenopausal and postmenopausal breast cancer incidence (30•6 and 253•6 cases per 100 000, respectively), whereas countries with low and medium HDI had the highest premenopausal and postmenopausal mortality, respectively (8•5 and 53•3 deaths per 100 000, respectively). When examining breast cancer trends, we noted significantly increasing age-standardised incidence rates (ASIRs) for premenopausal breast cancer in 20 of 44 populations and significantly increasing ASIRs for postmenopausal breast cancer in 24 of 44 populations. The growth exclusively at premenopausal ages largely occurred in high-income countries, whereas the increasing postmenopausal breast cancer burden was most notable in countries under transition.Interpretation We provide evidence of a rising burden of both premenopausal and postmenopausal breast cancer worldwide. Although early diagnosis and access to treatment remain crucial in low-income and middle-income countries, primary prevention efforts seeking to decrease exposure to known breast cancer risk factors are warranted in all world regions to curb the future breast cancer burden.

Quinolinate Phosphoribosyltransferase Promotes Invasiveness of Breast Cancer Through Myosin Light Chain Phosphorylation

“…Breast cancer is the most common malignant disease among women and represents a major healthcare burden ( 1 ). The incidence of breast cancer has been increasing worldwide, including in Taiwan ( 2 , 3 ).…”

Discovery of breast cancer risk genes and establishment of a prediction model based on estrogen metabolism regulation

“…Breast cancer is the most common malignant disease among women worldwide, accounting for 24% of new cancer cases and 15% of cancer deaths in 2018, and incident cases are expected to increase by more than 46% by 2040, according to the GLOBOCAN Cancer Tomorrow prediction tool, which will seriously endanger women's lives and health [1]. At present, people's understanding of breast cancer is deepening substantially, and new treatment strategies for tumors, including breast cancer, are continually emerging [2,3].…”

Cost-Effectiveness Analysis from a Randomized Controlled Trial of Tailored Exercise Prescription for Women with Breast Cancer with 8-Year Follow-Up

“…Although 5-year survival rates for localized breast cancer are high at~95% [2], incidence is also high (one in seven women will develop breast cancer [3]) with key lifestyle risk factors remaining widespread and growing. Risk factors for postmenopausal breast cancer include obesity, having fewer children, low levels of physical activity, reduced levels of breastfeeding, and having children later in life [4].…”